- Home
- USIO vs VTVT Comparison
USIO vs VTVT Comparison
Compare USIO & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- VTVT
- Stock Information
- Founded
- USIO 1998
- VTVT 2015
- Country
- USIO United States
- VTVT United States
- Employees
- USIO N/A
- VTVT N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- VTVT Health Care
- Exchange
- USIO Nasdaq
- VTVT Nasdaq
- Market Cap
- USIO 37.8M
- VTVT 38.8M
- IPO Year
- USIO N/A
- VTVT 2015
- Fundamental
- Price
- USIO $1.61
- VTVT $15.72
- Analyst Decision
- USIO Strong Buy
- VTVT Strong Buy
- Analyst Count
- USIO 2
- VTVT 1
- Target Price
- USIO $5.00
- VTVT $35.00
- AVG Volume (30 Days)
- USIO 795.8K
- VTVT 8.4K
- Earning Date
- USIO 03-26-2025
- VTVT 03-12-2025
- Dividend Yield
- USIO N/A
- VTVT N/A
- EPS Growth
- USIO N/A
- VTVT N/A
- EPS
- USIO 0.13
- VTVT N/A
- Revenue
- USIO $81,027,258.00
- VTVT $1,000,000.00
- Revenue This Year
- USIO $2.94
- VTVT N/A
- Revenue Next Year
- USIO $14.59
- VTVT N/A
- P/E Ratio
- USIO $12.37
- VTVT N/A
- Revenue Growth
- USIO N/A
- VTVT 11011.11
- 52 Week Low
- USIO $1.24
- VTVT $8.10
- 52 Week High
- USIO $2.92
- VTVT $30.99
- Technical
- Relative Strength Index (RSI)
- USIO 42.91
- VTVT 59.39
- Support Level
- USIO $1.77
- VTVT $13.96
- Resistance Level
- USIO $1.96
- VTVT $16.19
- Average True Range (ATR)
- USIO 0.21
- VTVT 0.55
- MACD
- USIO -0.10
- VTVT 0.26
- Stochastic Oscillator
- USIO 3.33
- VTVT 84.28
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for the Output Solutions operations.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Itsproduct pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.